What is the global market size of Sickle Cell Disease Treatment Market?

Sickle Cell Disease Treatment Market size was valued at USD 1.73 billion in 2021 and is poised to grow from USD 2.10 billion in 2022 to USD 9.91 billion by 2030, at a CAGR of 21.4% during the forecast period (2023-2030).

Who are the key vendors in the Global Sickle Cell Disease Treatment Market?

Global Sickle Cell Disease Treatment Market features a competitive landscape with several prominent players striving to develop effective therapies and treatments. These companies are actively engaged in research and development activities, clinical trials, and strategic collaborations to gain a competitive edge in the market. Key players in the market are investing significant resources in developing novel drugs, gene therapies, and supportive care options to address the complex challenges associated with sickle cell disease. Additionally, partnerships with academic institutions, research organizations, and patient advocacy groups are aiding in the advancement of innovative treatment approaches. With the increasing focus on precision medicine and personalized therapies, competition in the market is expected to intensify as companies strive to bring breakthrough treatments to the market and improve the lives of individuals living with sickle cell disease. 'Novartis (Switzerland)', 'Pfizer (US)', 'Global Blood Therapeutics (US)', 'Bluebird Bio (US)', 'Bristol Myers Squibb (US)', 'Sangamo Therapeutics (US)', 'Emmaus Life Sciences (US)', 'Eli Lilly and Company (US)', 'Modus Therapeutics (Sweden)', 'Gamida Cell (Israel)', 'Lonza Group (Switzerland)', 'Addmedica (France)', 'Selexys Pharmaceuticals (US)', 'GlycoMimetics (US)', 'Mast Therapeutics (US)', 'Acceleron Pharma (US)', 'Angiocrine Bioscience (US)', 'Imara Inc. (US)', 'AstraZeneca (UK)', 'Sanofi (France)'

What is the key driver of Global Sickle Cell Disease Treatment Market?

Gene therapy has emerged as a promising approach in the treatment of sickle cell disease. The development of gene-editing technologies, such as CRISPR-Cas9, has opened new possibilities for correcting the underlying genetic mutation responsible for SCD. For example, in 2020, the U.S. Food and Drug Administration (FDA) approved the first gene therapy for SCD, called Zynteglo. This therapy uses a patient's own stem cells, genetically modifying them to produce healthy hemoglobin and reduce the symptoms of the disease. The advancements in gene therapy offer hope for more effective and long-lasting treatments for SCD.

What is the key market trend for Global Sickle Cell Disease Treatment Market?

Personalized Medicine and Precision Therapies: There is a growing trend towards personalized medicine in the treatment of sickle cell disease. Advancements in genetic testing and understanding of individual genetic variations associated with SCD have paved the way for tailored treatment approaches. For instance, hydroxyurea, an FDA-approved medication for SCD, has demonstrated variable responses among patients. This has led to ongoing research to identify biomarkers and genetic factors that can predict treatment response, enabling the development of personalized treatment regimens for improved outcomes.

Which region accounted for the largest share in Sickle Cell Disease Treatment Market?

The Middle East and Africa region holds a significant market share, primarily due to the high prevalence of the condition in sub-Saharan Africa. This region faces a considerable burden of sickle cell disease, with a large number of affected individuals. As a result, there is a strong focus on improving treatment options and enhancing healthcare infrastructure to cater to the needs of patients. For example, in Nigeria, the country with the highest number of sickle cell disease cases globally, the government has launched initiatives to increase access to quality healthcare services and raise awareness about the disease. This has led to collaborations between healthcare providers, pharmaceutical companies, and research institutions to develop and deliver effective treatments.

Sickle Cell Disease Treatment Market Updates

Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to sickle cell disease treatment market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.

Sickle Cell Disease Treatment Market News

In May 2024, the National Health Service (NHS) announced the launch of a new drug for sickle cell disease treatment Voxelotor. The treatment was previously approved by National Institute for Health and Care Excellence (NICE) as it could potentially help improve the quality of life for people affected by sickle cell disease in the United Kingdom.
In March 2024, Akums Drugs and Pharmaceutical, a pharmaceutical contract manufacturing company based in India announced the launch of a new room-temperature treatment for sickle cell disease. The new oral suspension of Hydroxyurea treatment eliminates the need for cold storage and makes it more accessible to general people.
In December 2023, the United States Food and Drug Administration (FDA) announced the approval of first gene-based therapies for sickle cell disease treatment. Casgevy and Lyfgenia were the two novel treatments approved by the regulatory body and made available for patients of 12 years or older.

Sickle Cell Disease Treatment Market Report Snapshots

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

Sickle Cell Disease Treatment Market size was valued at USD 2.55 Billion in 2023 and is poised to grow from USD 3.1 Billion in 2024 to USD 14.6 Billion by 2032, growing at a CAGR of 21.4% during the forecast period (2025-2032).

Sickle cell disease treatment providers should focus on investing heavily in research and development to come up with novel treatments and therapies. Sickle cell disease treatment companies can also focus on gaining approvals for their novel treatment products and therapies from regulatory bodies and governments. Collaborations and partnerships are also expected to emerge as highly popular strategies for market players looking to enhance their revenue generation potential in the future. 'Novartis AG ', 'Emmaus Medical, Inc. ', 'Addmedica ', 'Medunik USA ', 'Global Blood Therapeutics, Inc. ', 'Bristol Myers Squibb Co. ', 'Sanofi SA ', 'Bluebird Bio ', 'Pfizer Inc. ', 'Aruvant Sciences, Inc. ', 'Glycomimetics, Inc. ', 'Editas Medicine, Inc. ', 'CRISPR Therapeutics ', 'F. Hoffmann-La Roche Ltd ', 'Janssen Pharmaceuticals ', 'Merck & Co., Inc. ', 'AstraZeneca ', 'Gilead Sciences ', 'Vertex Pharmaceuticals ', 'Hemanext'

Genetic predisposition and lack of early detection have resulted in a major hike in incidence of sickle cell disease around the world. Africa, India, and the Middle East are projected to key countries where the prevalence of sickle cell disease is high thereby making them highly opportune markets for sickle cell disease treatment providers as well.

Collaborations to Increase Accessibility: Sickle cell disease treatment availability varies from region to region, and this has resulted in low adoption of novel treatments and therapies. Governments, non-profit organizations, and healthcare companies can team to improve accessibility and affordability of treatments for patients around the world to boost revenue generation in the long run.

North America is estimated to lead the demand for sickle cell disease treatment on a global level. High investments in medical research, presence of a developed healthcare infrastructure, and high healthcare expenditure make this region a prime market for sickle cell disease treatment companies. Increasing willingness of patients in the United States to spend more on advanced treatment alternatives and growing medical tourism in the country allows it to emerge as the top market for sickle cell disease treatment companies operating in North America. Robust investments and advancements in gene therapies and technologies are also expected to help the dominance of this region in the long run.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Sickle Cell Disease Treatment Market

Report ID: SQMIG35D2091

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE